Literature DB >> 12820880

Interaction of fibrin(ogen) with heparin: further characterization and localization of the heparin-binding site.

Sergiy Yakovlev1, Sergey Gorlatov, Kenneth Ingham, Leonid Medved.   

Abstract

The beta chain 15-42 sequence of the fibrin(ogen) E region was implicated in heparin binding [Odrljin et al. (1996) Blood 88, 2050-2061]; whether heparin binds to other fibrin(ogen) regions remains to be clarified. To address this question, we studied the interaction of heparin with fibrinogen, fibrin, and their major fragments D(1), D-D, E(1), E(3), and alphaC, which together cover the entire structure of the molecule, by ligand blotting, surface plasmon resonance, and fluorescence. All three techniques revealed that at physiological ionic conditions only fibrin(ogen) and the E(1) fragment bind heparin, indicating that the only physiologically relevant heparin-binding site of fibrin(ogen) is located in its E region. To test whether the beta15-42 sequence is sufficient to form this site or some additional sequences are also involved, we tested the interaction of heparin with a number of beta15-42-containing fragments. The synthetic beta15-42 peptide bound heparin weakly (K(d) = 44.5 microM) while the recombinant beta15-57 and beta15-64 fragments exhibited almost 7-fold higher affinity (K(d) = 6.4 and 7.1 microM, respectively), indicating that the beta43-57 region is also important for heparin binding. At the same time the recombinant dimeric disulfide-linked (beta15-66)(2) fragment which mimics the dimeric arrangement of the beta chains in fibrin bound heparin with high affinity (K(d) = 66 nM), almost 100-fold higher than that for the monomeric fragments. This affinity was similar to those determined for fibrin and the E(1) fragment (K(d) = 72 and 70 nM, respectively) suggesting that (beta15-66)(2) mimics well the heparin-binding properties of the latter two. Altogether, these results indicate that the only heparin-binding site in fibrin(ogen) is formed by NH(2)-terminal portions of the beta chains, including residues beta15-57, and that dimerization is essential for high-affinity binding.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12820880     DOI: 10.1021/bi0344073

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  24 in total

1.  Zn2+ mediates high affinity binding of heparin to the αC domain of fibrinogen.

Authors:  James C Fredenburgh; Beverly A Leslie; Alan R Stafford; Teresa Lim; Howard H Chan; Jeffrey I Weitz
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

2.  Interaction of fibrin with VE-cadherin and anti-inflammatory effect of fibrin-derived fragments.

Authors:  S Yakovlev; Y Gao; C Cao; L Chen; D K Strickland; L Zhang; L Medved
Journal:  J Thromb Haemost       Date:  2011-09       Impact factor: 5.824

3.  Fibrin-VLDL Receptor-Dependent Pathway Promotes Leukocyte Transmigration by Inhibiting Src Kinase Fyn and is a Target for Fibrin β15-42 Peptide.

Authors:  Sergiy Yakovlev; Chunzhang Cao; Rebeca Galisteo; Li Zhang; Dudley K Strickland; Leonid Medved
Journal:  Thromb Haemost       Date:  2019-08-29       Impact factor: 5.249

4.  Heparin-binding domain of fibrin(ogen) binds growth factors and promotes tissue repair when incorporated within a synthetic matrix.

Authors:  Mikaël M Martino; Priscilla S Briquez; Adrian Ranga; Matthias P Lutolf; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

5.  Anti-VLDL receptor monoclonal antibodies inhibit fibrin-VLDL receptor interaction and reduce fibrin-dependent leukocyte transmigration.

Authors:  Sergiy Yakovlev; Alexey M Belkin; Ling Chen; Chunzhang Cao; Li Zhang; Dudley K Strickland; Leonid Medved
Journal:  Thromb Haemost       Date:  2016-09-01       Impact factor: 5.249

6.  Postinjury hyperfibrinogenemia compromises efficacy of heparin-based venous thromboembolism prophylaxis.

Authors:  Jeffrey N Harr; Ernest E Moore; Theresa L Chin; Arsen Ghasabyan; Eduardo Gonzalez; Max V Wohlauer; Angela Sauaia; Anirban Banerjee; Christopher C Silliman
Journal:  Shock       Date:  2014-01       Impact factor: 3.454

7.  Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.

Authors:  Galina Tsurupa; Sergiy Yakovlev; Patrick McKee; Leonid Medved
Journal:  Biochemistry       Date:  2010-09-07       Impact factor: 3.162

8.  Effect of fibrinogen, fibrin, and fibrin degradation products on transendothelial migration of leukocytes.

Authors:  Sergiy Yakovlev; Leonid Medved
Journal:  Thromb Res       Date:  2017-11-21       Impact factor: 3.944

9.  Fibrinogen Protects Against Barrier Dysfunction Through Maintaining Cell Surface Syndecan-1 In Vitro.

Authors:  Feng Wu; Rosemary A Kozar
Journal:  Shock       Date:  2019-06       Impact factor: 3.454

10.  A novel fragment derived from the beta chain of human fibrinogen, beta43-63, is a potent inhibitor of activated endothelial cells in vitro and in vivo.

Authors:  E Krajewska; C E Lewis; Y-Y Chen; A Welford; S Tazzyman; C A Staton
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.